NextCure, Inc. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of NextCure, Inc.'s 2022 Annual Meeting of Stockholders held on June 23, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Beltsville, Maryland. Its common stock trades on the Nasdaq Global Select Market under the symbol NXTC.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of two proposals submitted to stockholders:
- Proposal 1: Election of Class III Directors
- David Kabakoff, Ph.D.: Elected with 11,548,824 votes For, 1,187,004 Against, and 245,392 Abstain.
- Michael Richman: Elected with 11,609,302 votes For, 1,124,238 Against, and 247,680 Abstain.
- Stephen W. Webster: Elected with 11,530,304 votes For, 1,202,184 Against, and 248,732 Abstain.
- All three directors were elected to serve three-year terms expiring at the 2025 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Voting results: 17,631,748 For, 53,399 Against, and 79,774 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting process.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific term expiration dates for the newly elected Class III directors (2025).
- Note the significant number of broker non-votes (4,783,701) recorded for the director elections, which indicates shares held by brokers that were not voted on these matters.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.